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Purpose: Prior work suggests a threshold of four courses/year of systemic corticosteroid (SCS) 
therapy is associated with adverse consequences. The objective of this study was to investigate 
the onset of adverse outcomes beginning at SCS initiation in a broad asthma population.
Patients and methods: This historical matched cohort study utilized anonymized, longitudinal 
medical record data (1984–2017) of patients (≥18 years) with active asthma. Matched patients 
with first SCS prescription (SCS arm) and no SCS exposure (non-SCS arm) were followed 
until first outcome event. Associations between time-varying exposure measures and onset of 
17 SCS-associated adverse outcomes were estimated using Cox proportional hazard regression, 
adjusting for confounders, in separate models.
Results: We matched 24,117 pairs of patients with median record availability before SCS ini-
tiation of 9.9 and 8.7 years and median follow-up 7.4 and 6.4 years in SCS and non-SCS arms, 
respectively. Compared with patients in the non-SCS arm, patients prescribed SCS had significantly 
increased risk of osteoporosis/osteoporotic fracture (adjusted hazard ratio 3.11; 95% CI 1.87–5.19), 
pneumonia (2.68; 2.30–3.11), cardio-/cerebrovascular diseases (1.53; 1.36–1.72), cataract 
(1.50; 1.31–1.73), sleep apnea (1.40; 1.04–1.86), renal impairment (1.36; 1.26–1.47), depression/
anxiety (1.31; 1.21–1.41), type 2 diabetes (1.26; 1.15–1.37), and weight gain (1.14; 1.10–1.18). 
A dose-response relationship for cumulative SCS exposure with most adverse outcomes began 
at cumulative exposures of 1.0–<2.5 g and for some outcomes at cumulative exposures of only 
0.5–<1 g (vs >0–<0.5 g reference), equivalent to four lifetime SCS courses.
Conclusion: Our findings suggest urgent need for reappraisal of when patients need specialist 
care and consideration of nonsteroid therapy.
Keywords: adverse outcomes, asthma, cumulative exposure, oral corticosteroids, systemic 
corticosteroids
Introduction
Systemic corticosteroids (SCS) are commonly prescribed to treat patients with respira-
tory conditions such as asthma and to treat or reduce the risk of flare-ups of inflamma-
tory conditions, such as rheumatologic and autoimmune diseases, allergic reactions, 
and inflammatory bowel disease.1,2 However, the concern with maintenance SCS use 
is increased risk of infections and cardiovascular events; of chronic conditions such 
as type 2 diabetes mellitus, osteoporosis, and cataracts; of metabolic effects such 
as weight gain; and of neuropsychiatric effects such as insomnia, depression, and 
behavioral disturbances.3–5 A dose-response relationship with SCS exposure has been 
documented for many of these events.6–9 Even short-term use of oral corticosteroids 
(OCS) in a large population-based study has been associated with increased rates of 
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sepsis, thromboembolism, and fracture within 30 days of 
OCS initiation.10 Of note, decreases in serum cortisol and 
markers of bone formation, and changes in white blood cell 
counts, are evident within hours of oral prednisone admin-
istration to healthy subjects.11
SCS, usually prescribed orally, are a mainstay of treat-
ment for asthma exacerbations and are often prescribed as 
part of daily maintenance therapy for patients with severe 
asthma.12 An increased risk of adverse outcomes associated 
with regular SCS exposure has been recorded in severe asthma 
populations.8,9 In a recent cross-sectional, on-treatment study 
in the UK,13 93% of patients with severe asthma had one or 
more conditions linked to SCS exposure, including type 2 
diabetes, osteoporosis, dyspeptic disorders (gastric/duodenal 
ulcers), and cataracts. There are little data available, however, 
regarding the onset of SCS-associated adverse outcomes 
from the time of SCS initiation in a broad asthma popula-
tion not restricted to those with severe disease. Moreover, 
additional data are needed to help confirm the relationship 
between cumulative SCS exposure and these outcomes, and 
the threshold exposure above which the risk of comorbid dis-
ease onset meaningfully increases.5,14,15 Of note, 1 g of SCS is 
equivalent to four short courses of OCS at the usual doses for 
treating an asthma exacerbation.12 Existing work suggests that 
a threshold of four SCS courses per year is associated with 
adverse consequences in patients with asthma.13,15
The aim of this study was to investigate the impact of 
initiating SCS, and of SCS exposure, on the onset of known 
SCS-associated adverse outcomes over a minimum of 2 years 
in a broad population of patients with active asthma of all 
levels of severity. Patients included in these analyses met the 
a priori definition for active asthma, which included a diag-
nostic Read code recorded within 1 year before or after (and 
including) the index date and at least two prescriptions for 
asthma medication in this period (reliever and/or controller 
medication). The prespecified adverse outcomes of interest 
included type 2 diabetes mellitus, cardio-/cerebrovascular 
diseases (myocardial infarction, heart failure, and stroke), 
dyslipidemia, hypertension, weight gain, osteoporosis, 
osteoporotic fracture, glaucoma, cataract, renal impairment, 
peptic ulcer disease, depression/anxiety, sleep apnea, and 
pneumonia.
Patients and methods
study design overview and data sources
This was a historical matched cohort study of patients with 
active asthma comparing those initiating SCS (SCS arm) with 
those not exposed to SCS (non-SCS arm). The study comprised 
a minimum 1-year baseline period and a minimum 2-year 
follow-up period, on either side of an index date (Figure 1). 
The index date for patients in the SCS arm was the date of 
their first recorded prescription for parenteral or OCS, whereas 
the index date for those in the non-SCS arm was the nearest 
general practitioner (GP) visit to the matched case index date.
We utilized anonymized, longitudinal medical record 
data (January 1984 through January 2017) drawn from the 
Optimum Patient Care Research Database (OPCRD)16 and 
the Clinical Practice Research Datalink (CPRD).17 These 
large databases both include routinely collected data from 
medical records centralized in the UK at each patient’s GP, 
such as diagnoses, prescriptions, clinical investigations, and 
hospital referrals and admissions. The OPCRD included over 
3 million active patient records at the time of the study and 
the CPRD, over 5 million active patient records.
The study adhered to standards recommended for obser-
vational research (details in Supplementary material).18 The 
protocol was approved by the CPRD Independent Scientific 
Advisory Committee (ISAC reference number 17_002) and 
the Anonymized Data Ethics Protocols and Transparency 
committee (ADEPT Approval Reference ADEPT0117), the 
independent scientific advisory committee for the OPCRD.16 No 
patient-identifying information was accessible during the study.
Patient population
Patients eligible for the study were ≥18 years of age and had 
active asthma and ≥3 years of continuous practice records 
(including ≥1-year baseline and ≥2-year follow-up peri-
ods). Active asthma was defined as a diagnostic Read code 
recorded within 1 year before or after (and including) the 
index date and at least two prescriptions for asthma medica-
tion in this period (reliever and/or controller medication). 
Patients in the SCS arm had to have asthma as the most likely 
indication for their first SCS prescription plus ≥1 additional 
prescription(s) for SCS within the next 18 months. A first 
SCS prescription was defined as no recorded prescription 
ever before the index date in the available data.
Patients were excluded from the analyses if their records 
contained a tamoxifen prescription for breast cancer at any 
time or diagnostic codes for adrenal insufficiency at any 
time or for cancer within 5 years before or 3 months after the 
index date. In addition, for the non-SCS arm, patients were 
excluded if they ever had any recorded prescriptions of SCS 
in the available data. Exclusion criteria for specific outcome 
(risk) cohorts are listed in Table S1.
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study variables and outcomes
The exposure of interest was SCS identified as any pre-
scription for systemic prednisolone, methylprednisolone, 
prednisone, betamethasone, dexamethasone, hydrocortisone, 
or cortisone acetate, either as monotherapy or combination 
therapy. For patients in the SCS arm, we estimated the cumu-
lative exposure of SCS (in grams, prednisolone-equivalent) 
and mean daily exposure (mg/day) calculated as cumulative 
prednisolone-equivalent exposure divided by follow-up dura-
tion (Supplementary material).
The adverse outcomes (Table 1) were analyzed for patients 
who had no clinical diagnosis or other indications (medication 
use, laboratory measurements) specific to each given outcome 
before the index date (Table S1). Thus, separate risk cohorts 
were constructed for each adverse outcome under study.
Patient matching
Matching within the CPRD was conducted first, followed 
by matching in the OPCRD. Patients from the OPCRD who 
had identical values on the following variables as patients 
from the CPRD were removed from the combined database: 
index date, age, sex, practice joining date, practice leaving 
date, and asthma diagnosis; while duplicate controls were 
identified using index date, age, sex, practice joining date, 
and practice leaving date.
We first conducted 1:1 matching for sex, diagnosis of 
asthma, the index date (maximum distance of 182 days), and 
the availability of Hospital Episode Statistics (HES) link-
age. The HES data, linked to CPRD, were used to identify 
hospital-related events.19 We then retained only the patients 
with active asthma (see above for definition), together with 
their matched counterparts.
statistical analysis
Descriptive statistics of all baseline characteristics were com-
puted in the matched sample. We evaluated the quality of the 
matching using the standardized mean difference20 in combina-
tion with the bias potential21 (details in Supplementary material).
The incidence rate of each adverse outcome in the 
SCS and non-SCS arms, as cases per 100 patient-years of 
Figure 1 study design.
Abbreviations: cPrD, clinical Practice research Datalink; gP, general practitioner; Ocs, oral corticosteroid; OPcrD, Optimum Patient care research Database; scs, 
systemic corticosteroid.
Index date
SCS arm: first recorded prescription of parenteral or OCS
Non-SCS arm: matched nearest date of contact with GP to corticosteroid arm index date date
Broad population captured in
OPCRD and CPRD:
•  Age ≥18 years 
•  Asthma diagnosis
•  No recorded parenteral or OCS
prescriptions before index date 
•  No adrenal insufficiency
•  No cancer within 5 years before or 
3 months after index date or
tamoxifen for breast cancer at
any time 
SCS arm
Non-SCS arm
≥1 additional prescription for SCS
within 18 months after first recorded
SCS prescription
No recorded parenteral or OCS
prescription ever
For time-to-onset analysis: Patients followed until the first occurrence of any of 
the following: onset of outcome condition or death, leaving the general practice,
end of available records, or last date of extraction
Baseline period
(minimum 1 year)
Follow-up period
(minimum 2 years)
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 follow-up (100 pt-yr), was compared using the incidence 
rate difference and the incidence rate ratio (IRR) with 95% 
CIs. Each patient was followed until the first occurrence of 
the outcome of interest and was censored at death or the end 
of available records. We used conditional multivariable Cox 
proportional hazard models with 95% CIs to compare the 
risk of adverse outcomes between SCS and non-SCS arms 
and account for the clustered nature of the matched data.
In the SCS arm, the cumulative SCS exposure and the 
mean daily exposure, both as continuous and categorized 
variables, were modeled as time-dependent exposures to 
assess their association with the development of each out-
come using a time-to-event design. We used multivariable 
Cox proportional hazard models with 95% CIs to determine 
risk of each outcome from SCS exposure.
For each outcome model, three sets of confounding vari-
ables were defined a priori based on clinical knowledge for 
each risk cohort (Table S2): (1) variables that were always 
adjusted for, (2) variables available for bias potential assess-
ment during model building (process described in Supple-
mentary material), and (3) variables that were not considered 
in the models. Confounders applied to the adjusted models 
are provided in Table S3.
Table 1 Outcomes evaluated after the index date in each risk cohort
Outcome Definition applied after the index date (during follow-up period)a
Type 2 diabetes mellitus •	 Diagnosis of type 2 diabetes mellitus and/or
•	 One or more prescriptions for antidiabetic medicationb and/or
•	 hbA1c value ≥6.5%
cardio-/cerebrovascular disease •	 Myocardial infarction, heart failure, or stroke diagnosis
Myocardial infarction •	 Myocardial infarction diagnosis
heart failure •	 heart failure diagnosis
cerebrovascular accident •	 cerebrovascular accident diagnosis
Dyslipidemia •	 Dyslipidemia diagnosis and/or total cholesterol reading >6.5 mmol/l, and/or low-density lipoprotein reading 
>4 mmol/l, and/or triglyceride reading ≥2.3 mmol/l
hypertension •	 hypertension diagnosis
Weight gain •	 An increase in BMi of ≥1 kg/m2 compared with the last BMi in the 5 years before the index date
Osteoporosis diagnosis •	 Osteoporosis diagnosis
  Osteoporosis and osteoporotic 
fracture
•	 Osteoporosis diagnosis AnD
•	 likely osteoporotic fracture (hip, wrist, or vertebral fracture)
glaucoma •	 glaucoma diagnosis and/or treatment for glaucoma
cataract •	 cataract diagnosis or surgery for cataract
renal impairment •	 chronic kidney disease stage 3a+ diagnosis, or egFr <60 ml/min/1.72 m2, or dialysis or renal transplant
Peptic ulcer •	 Peptic ulcer diagnosis
Depression/anxiety •	 Depression/anxiety diagnosis or depression/anxiety diagnosis and prescription of antidepressants
sleep apnea •	 sleep apnea diagnosis and/or referral to sleep clinic and use of a continuous positive airway pressure device
Pneumonia •	 Pneumonia diagnosis
Notes: aDiagnoses were defined as diagnostic Read codes recorded after the index date. See Table s1 for exclusion criteria specific to each risk cohort. bPatients with a 
diagnosis of polycystic ovary syndrome (PcOs) and ≥1 metformin prescriptions in the follow-up period were excluded because metformin is given as treatment for PcOs.
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate.
Dataset creation was performed using SAS version 9.4 
(SAS Institute, Cary, NC, USA), and statistical analyses 
were conducted using Stata SE version 14.2 and Stata MP/6 
version 15.0 (StataCorp, College Station, TX, USA). Results 
were considered statistically significant if P≤0.05.
Results
Patients
Overall, the databases contained 307,213 matched pairs of 
patients. Of these, 117,409 (38%) patients in the SCS arm 
were prescribed SCS for asthma, 58,577 (19%) for COPD, 
and 1,536 (0.5%) for asthma and COPD. We analyzed data 
for the 24,117 matched pairs (48,234 total patients) who had 
study-defined active asthma. This represented 21% of the 
117,409 matched pairs of patients with an SCS prescription 
for asthma. More than 99% of patient pairs were matched 
on the same index date (ie, the date of first SCS prescrip-
tion for patients in the SCS arm). For 18,291 (76%) patient 
pairs, the index date was in the year 2000 or later, and for 
13,522 (56%), 2005 or later.
In the SCS arm, the mean record availability before 
initiation of SCS (preindex date) was 14.3 years (median 
9.9 years; IQR 4.1–20.0) and in the non-SCS arm, the mean 
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 preindex record availability was 12.8 years (median 8.7 
years; IQR 3.7–18.2). Overall, 17,246 (72%) and 17,540 
(73%) patient pairs in SCS and non-SCS arms, respec-
tively, had 4 or more years of medical record data available 
before the index date. The mean follow-up time (postindex 
date) was 8.7 years in the SCS arm (median 7.4 years; IQR 
4.5–11.2) and 7.7 years in the non-SCS arm (median 6.4 
years; IQR 3.8–10.0).
The mean ages of the matched SCS and non-SCS arms 
were 49 (SD 17) and 44 (SD 18) years, respectively; and 
15,585 (65%) in each cohort were women (Table 2). In 
the SCS arm, more patients were obese (5,570 [33%] vs 
4,524 [26%] in non-SCS arm) and current smokers (8,604 
[37%] vs 7,373 [32%]) at baseline. A greater percentage of 
patients in the SCS arm were treated with antibiotics for 
one or more infections, respectively, during the baseline 
year (Table 2).
Of 305,110 SCS prescriptions included in the analyses, 
the majority (299,785; 98%) were for OCS and 5,325 (2%) 
were for parenteral corticosteroids.
incidence of adverse outcomes by scs use
In all risk cohorts, patients in the SCS arm, irrespective of 
treatment regimen, experienced a significantly higher inci-
dence of the study outcome compared with the non-SCS arm 
(Table 3). Pneumonia had the greatest relative incidence with 
SCS use (IRR 2.92; 95% CI 2.60–3.29). Osteoporosis diag-
nosis and fracture had the second greatest relative incidence 
with SCS use (IRR 2.84; 95% CI 2.05–3.98), even though 
it was the least common outcome, with 0.085 and 0.030 
events per 100 person-years recorded in SCS and non-SCS 
arms, respectively. The onset of type 2 diabetes was one of 
the most common adverse outcomes, with 1.047 vs 0.615 
events per 100 person-years for patients with and without 
SCS use, respectively, and an IRR of 1.70 (1.58–1.84) for 
SCS vs non-SCS arms (Table 3).
For the SCS arm (vs non-SCS arm), the adjusted risk of 
the onset of an adverse outcome was significantly greater for 
13 of 17 outcomes, namely, excepting the onset of dyslipid-
emia, hypertension, glaucoma, and peptic ulcer. For these 13 
outcomes, the adjusted risk in the SCS arm compared with 
the non-SCS arm ranged from 1.14 times greater for weight 
gain (BMI increase of ≥1 kg/m2) to 3.11 times greater for 
new osteoporosis diagnosis/osteoporotic fracture (Figure 2).
cumulative scs exposure and adverse 
outcomes in the scs arm
A positive dose-response relationship was present between 
categorized, cumulative SCS exposure and adverse 
 outcome in most risk cohorts, except dyslipidemia, hyper-
tension, weight increase, and glaucoma (Figure 3). This 
positive dose-response relationship was evident at the 
lowest exposure categories, with increasing risk of most 
outcomes evident and becoming statistically significant 
when progressing from a cumulative SCS exposure of 
0.5 to <1 g to a cumulative SCS exposure of 1.0 to <2.5 g 
compared with the reference category of >0 to <0.5 g SCS 
(Figure 3). For example, the risk of type 2 diabetes onset 
was 16% higher at cumulative SCS exposure of 0.5 to <1 g 
(vs reference >0–<0.5 g: adjusted hazard ratio [aHR] 1.16; 
95% CI 1.01–1.34) and increased to 37% at cumulative SCS 
exposure of 1.0 to <2.5 g (aHR 1.37; 95% CI 1.18–1.58). 
Further details for each SCS exposure category and risk 
cohort are presented in Table S4.
For cumulative SCS dose as a continuous variable, a 
significantly increased risk was recorded for all outcomes 
except hypertension and weight gain per 1-g increase, with 
most increases in the range of 1.02–1.03 times (2%–3%; 
Table S4).
Mean daily scs exposure and adverse 
outcomes in the scs arm
A positive dose-response relationship between mean daily 
SCS exposure and each outcome studied was also evident 
compared with the reference category of >0 to <0.5 mg/
day exposure, as summarized in Table S5. At a mean daily 
SCS exposure of 0.5 to <2.5 mg/day, the aHR ranged from 
1.77 (95% CI 1.59–1.96) for hypertension to 3.10 (95% CI 
2.64–3.63) for osteoporosis diagnosis; at a mean daily SCS 
exposure of ≥7.5 mg/day, the aHR ranged up to 14.7 (95% 
CI 11.12–19.49) for osteoporosis diagnosis. For every 5-mg 
increase in mean daily exposure, the adjusted risk of each 
outcome increased from 21% to 70% (Table S5).
Discussion
In this large historical cohort study, we found that patients 
with active asthma experienced a significantly higher onset of 
prespecified adverse outcomes after their first SCS prescrip-
tion than matched controls not exposed to SCS. Patients in 
the SCS arm were at significantly increased risk of develop-
ing osteoporosis/osteoporotic fracture, pneumonia, cardio-/
cerebrovascular diseases (including myocardial infarction, 
heart failure, cerebrovascular accident), cataract, sleep apnea, 
renal impairment, depression/anxiety, type 2 diabetes, and 
weight gain. Moreover, among patients in the SCS arm, we 
found a positive dose-response relationship with multiple 
adverse outcomes regarding both cumulative SCS exposure 
and mean daily SCS exposure. This relationship was both 
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Table 2 Baseline characteristics of the matched treatment arms
Non-SCS
(n=24,117)
SCS
(n=24,117)
SMD (%)
sex, femalea 15,585 (65%) 15,585 (65%) 0.0
Age at index date (years) 43.9 (18.1) 48.7 (16.9) 27.4
18–40 11,958 (50%) 8,519 (35%) 23.5
41–60 7,072 (29%) 9,055 (38%)
61–80 4,342 (18%) 5,893 (24%)
>80 745 (3%) 650 (3%)
First scs and matched non-scs, median year (iQr)a 2,005 (9.0) 2,005 (9.0) 0.0
Available hes data linkagea 9,413 (39%) 9,413 (39%) 0.0
Body mass index (kg/m2), n (% nonmissing)b 17,466 (72%) 16,810 (70%) 18.8
<18.5 435 (2%) 328 (2%)
≥18.5 to <25 6,996 (40%) 5,439 (32%)
≥25 to <30 5,511 (32%) 5,473 (33%)
≥30 4,524 (26%) 5,570 (33%)
smoking status, n (% nonmissing)b 23,281 (97%) 23,587 (98%) 13.7
current smoker 7,373 (32%) 8,604 (36%)
ex-smoker 4,061 (17%) 4,773 (20%)
nonsmoker 11,847 (51%) 10,210 (43%)
ginA stepc,d
no medication 2,302 (10%) 4,454 (18%) 2.4
step 1 4,590 (19%) 3,970 (16%)
step 2 9,512 (39%) 6,386 (26%)
step 3 4,761 (20%) 4,972 (21%)
step 4 2,952 (12%) 4,335 (18%)
high-dose ics (mean dose >500 µg/day)b 1,029 (4%) 1,676 (7%) 11.7
FDc ics/lABA: ics daily dose (µg/day)c
0 7,109 (30%) 8,692 (36%) 2.4
>0–400 15,284 (63%) 12,792 (53%)
>400–800 1,357 (6%) 2,002 (8%)
>800 367 (2%) 631 (3%)
sABA (µg/day)c
0 5,062 (21%) 4,761 (20%) 7.3
1–100 4,247 (18%) 4,614 (19%)
101–200 6,214 (26%) 5,327 (22%)
201–400 4,558 (19%) 4,370 (18%)
>400 4,036 (17%) 5,045 (21%)
infections treated with antibioticsc
0 20,476 (85%) 14,799 (61%) 49.0
1 2,343 (10%) 5,747 (24%)
2 868 (4%) 2,361 (10%)
≥3 430 (2%) 1,210 (5%)
conditions recorded ever, before index date
Type 2 diabetes mellituse 1,223 (5%) 931 (4%) 5.9
cardio-/cerebrovascular disease 1,037 (4%) 1,016 (4%) 0.4
Myocardial infarction 420 (2%) 458 (2%) 1.2
heart failure 294 (1%) 255 (1%) 1.5
cerebrovascular accident 471 (2%) 426 (2%) 1.4
Dyslipidemia 2,964 (12%) 3,211 (13%) 3.1
hypertension 3,754 (16%) 4,145 (17%) 4.4
Osteoporosis 319 (1%) 383 (2%) 2.2
Osteoporosis or osteoporotic fracture 1,400 (6%) 1,565 (6%) 2.8
glaucoma 258 (1%) 293 (1%) 1.4
cataract diagnosis or surgery 727 (3%) 768 (3%) 1.0
renal impairmentf 2,004 (8%) 2,204 (9%) 2.0
Peptic ulcer 427 (2%) 553 (2%) 3.7
(Continued)
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statistically significant and clinically important, as increased 
risks of adverse outcomes were seen at relatively low cumula-
tive and mean daily SCS exposures.
We examined several categories of cumulative SCS 
exposure for patients in the SCS arm from the time of 
their first SCS prescription. Relative to the reference cat-
egory of >0 to <0.5 g, a statistically significant increased 
Table 3 incidence of outcomes of interest in the matched non-scs and scs arms
Risk cohort Non-SCS SCS IR difference
(95% CI)
Unadjusted IR 
ratio (95% CI)N Pt-yr No. 
events
IR (per  
100 pt-yr)
N Pt-yr No.  
events
IR (per 
100 pt-yr)
Type 2 diabetes mellitus 21,808 166,756 1,025 0.615 21,808 183,458 1,921 1.047 0.432 (0.372–0.493) 1.70 (1.58–1.84)
cardio-/cerebrovascular 
disease
22,112 169,323 826 0.488 22,112 185,195 1,774 0.958 0.470 (0.414–0.526) 1.96 (1.81–2.14)
Myocardial infarction 23,251 178,974 298 0.167 23,251 199,249 646 0.324 0.158 (0.126–0.189) 1.95 (1.69–2.24)
heart failure 23,570 181,201 349 0.193 23,570 200,790 858 0.427 0.235 (0.200–0.270) 2.22 (1.96–2.52)
cerebrovascular 
accident
23,228 178,454 451 0.253 23,228 198,519 823 0.415 0.162 (0.125–0.199) 1.64 (1.46–1.84)
Dyslipidemia 16,903 129,550 2,346 1.811 16,903 139,700 3,523 2.522 0.711 (0.600–0.822) 1.39 (1.32–1.47)
hypertension 12,248 95,871 986 1.028 12,248 104,340 1,626 1.558 0.530 (0.431–0.629) 1.52 (1.40–1.64)
Weight gain (BMi increase 
≥1 kg/m2)
12,894 53,496 6,718 12.558 12,894 52,680 7,677 14.573 2.015 (1.572–2.458) 1.16 (1.12–1.20)
Osteoporosis diagnosis 23,422 179,971 382 0.212 23,422 198,056 964 0.487 0.274 (0.237–0.312) 2.29 (2.03–2.59)
Osteoporosis diagnosis 
and fracture
21,251 166,344 50 0.030 21,251 186,270 159 0.085 0.055 (0.040–0.071) 2.84 (2.05–3.98)
glaucoma 23,424 180,109 273 0.152 23,424 201,118 433 0.215 0.064 (0.037–0.091) 1.42 (1.22–1.66)
cataract 22,648 173,139 830 0.479 22,648 190,051 1,736 0.913 0.434 (0.380–0.488) 1.91 (1.75–2.07)
renal impairment 20,137 152,844 1,758 1.150 20,137 162,698 3,215 1.976 0.826 (0.739–0.913) 1.72 (1.62–1.82)
Peptic ulcer 23,149 177,768 135 0.076 23,149 199,008 219 0.110 0.034 (0.015–0.054) 1.45 (1.16–1.81)
Depression/anxiety 7,961 62,801 1,257 2.002 7,961 66,924 1,554 2.322 0.320 (0.161–0.480) 1.16 (1.08–1.25)
sleep apnea 23,980 184,930 84 0.045 23,980 207,072 205 0.099 0.054 (0.037–0.070) 2.18 (1.68–2.84)
Pneumonia 24,065 184,422 379 0.206 24,065 203,107 1,220 0.601 0.395 (0.356–0.435) 2.92 (2.60–3.29)
Abbreviations: BMi, body mass index; ir, incidence rate; pt-yr, patient-years; scs, systemic corticosteroid.
Non-SCS
(n=24,117)
SCS
(n=24,117)
SMD (%)
Depression/anxiety 6,109 (25%) 7,088 (29%) 9.1
sleep apnea 69 (0.3%) 71 (0.3%) 0.2
Pneumonia in the prior yearc 68 (0.3%) 117 (0.5%) 3.3
charlson comorbidity indexg
0–4 10,778 (45%) 11,070 (46%) 5.6
5–8 10,325 (43%) 9,995 (41%)
9–12 827 (3%) 804 (3%)
13–16 829 (3%) 952 (4%)
≥17 1,358 (6%) 1,296 (5%)
Notes: Unless otherwise noted, data are n (%), mean (sD), or median (iQr). Percentages may not add up to 100 because of rounding. aMatching variable. bThe closest body 
mass index within 5 years before and the smoking status closest to index date were included. High-dose ICS (fluticasone propionate–equivalent dose) refers to the last 
prescription before or on the index date. cVariables assessed during the prior year (baseline). The ICS dose was the fluticasone propionate–equivalent dose. dThe ginA step 
was based on the last asthma medication(s) prescribed during the baseline year, including the index date. For the determination of ginA step in the scs arm, “no medication” 
was defined as no asthma-related medication other than SCS prescribed at the index date. No patients were receiving biologics or at GINA step 5. eType 2 diabetes mellitus 
diagnostic read code or hbA1c≥6.5% recorded twice or more. fstage 3a or higher at most recent assessment before the index date. ggreater scores predict increased 10-
year risk of mortality for people with multiple comorbidities. 
Abbreviations: FDC, fixed-dose combination; GINA, Global Initiative for Asthma; HES, Hospital Episode Statistics; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; 
sABA, short-acting β-agonist; sMD, standardized mean difference; scs, systemic corticosteroid.
Table 2 (Continued)
risk for onset of type 2 diabetes (aHR 1.16) was evident 
at a cumulative exposure of only 0.5 to <1 g SCS and for 
multiple other adverse outcomes at cumulative exposure 
of 1.0 to <2.5 g SCS. We note that 1 g SCS is equivalent 
to four short courses of OCS at the usual doses for treating 
an asthma exacerbation.12 Thus, an important clinical, as 
well as practical, implication of our findings is that patients 
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should be evaluated and considered for alternative treat-
ment strategies early in the course of their asthma to avoid 
the need for OCS.
Although SCS are well-established drugs, available 
generically, and thus inexpensive, health-care resource utili-
zation studies show a substantial impact from the associated 
adverse outcomes and their treatment.3,22,23 Furthermore, a 
positive dose-response relationship between long-term SCS 
exposure and health-care resource utilization and costs was 
recently found for patients with active asthma.23 The cost ratio 
(95% CI) associated with SCS use compared with non-SCS 
use increased from 1.25 (1.18–1.31) for 0.5–<2.5 mg/day to 
2.41 (2.02–2.88) for 7.5–<15.0 mg/day and 3.86 (2.53–5.89) 
for ≥15.0 mg/day.23 We found that most SCS was prescribed 
for respiratory conditions (for a total of 177,522 matched 
pairs of patients in the database, or 58%), primarily for 
asthma. Results of the continuous exposure model for a 
1-g increase in cumulative exposure to SCS might suggest 
that effects of exposure are low, with significant HRs in the 
1.02–1.03 range; however, it is important to note that this 
Figure 2 HR (95% CI) for each adverse outcome in the SCS arms (vs non-SCS arms). The open squares represent unadjusted, and the closed squares, adjusted results. The 
adjusted hrs (95% cis) are shown on the right. see Table s3 for list of confounders.
Abbreviations: BMi, body mass index; scs, systemic corticosteroid.
SCS vs non-SCS
Osteoporosis diagn/frac (N=42,502, events =209)
Pneumonia (N=48,130, events =1,599)
Osteoporosis diagnosis (N=46,844, events =1,346)
Heart failure (N=47,140, events =1,207)
Cardio-/cerebrovascular disease (N=44,224, events =2,600)
Cataract (N=45,296, events =2,566)
Myocardial infarction (N=46,502, events =944)
Sleep apnea (N=47,960, events =289)
Renal impairment (N=40,274, events =4,973)
Depression/anxiety (N=15,922, events =2,811)
Cerebrovascular accident (N=46,456, events =1,274)
Peptic ulcer (N=46,298, events =354)
Type 2 diabetes mellitus (N=43,616, events =2,946)
Glaucoma (N=46,848, events =706)
BMI increase (N=25,788, events =14,395)
Hypertension (N=24,496, events =2,612)
Dyslipidemia (N=33,806, events =5,869)
3.11 (1.87–5.19)
2.68 (2.30–3.11)
1.96 (1.63–2.34)
1.63 (1.32–2.00)
1.53 (1.36–1.72)
1.50 (1.31–1.73)
1.41 (1.15–1.73)
1.40 (1.04–1.86)
1.36 (1.26–1.47)
1.31 (1.21–1.41)
1.30 (1.10–1.55)
1.28 (0.94–1.74)
1.26 (1.15–1.37)
1.23 (0.99–1.53)
1.14 (1.10–1.18)
1.06 (0.97–1.16)
1.03 (0.97–1.09)
HR
0.9 1.5 2.5 3.5 54321
model  incorporates the assumption that average effect is 
independent of the initial exposure level, meaning that a 1-g 
increase from 0 to 1 g total dose would result in the same risk 
increase as an increase from 4 to 5 g. The results from the 
categorical model show that this assumption does not hold 
true, as the HR for patients with 10-g cumulative exposure 
was more than two times greater than that at the lowest 
category of exposure for most adverse outcomes, whereas 
a 22% to 34% increased risk would be estimated from the 
continuous model (1.0210–1.0310).
The results from the daily exposure analyses show a clear, 
positive dose-response relationship consistent with that seen 
with cumulative exposure. For example, the risk of onset 
of type 2 diabetes is almost nine times greater for patients 
prescribed >7.5 mg/day vs 0–<0.5 mg/day. These findings, 
which incorporate both duration and dosage, are challenging 
to translate into a specific clinical recommendation; however, 
of note, we observed the increase at even very low daily 
exposures and can conclude that minimizing SCS exposure 
should be an important goal of asthma therapy.
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Figure 3 (A–C) Adjusted hazard ratio (95% ci) for each adverse outcome in the scs arms for categorized, cumulative scs exposures, compared with the reference 
category of >0 to <0.5-g cumulative exposure. see Table s3 for list of confounders.
Abbreviations: BMi, body mass index; scs, systemic corticosteroid.
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Reference
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1.48 (0.96–2.30)
1.17 (0.77–1.77)
Reference
1.85 (1.55–2.21)
1.34 (1.14–1.57)
1.23 (1.07–1.42)
1.20 (1.08–1.34)
1.05 (0.95–1.16)
Reference
A
B
C
Our findings support those of the recent study of Sullivan 
et al,15 while the high granularity data in the OPCRD and 
CPRD enabled us to further characterize the association of 
adverse outcomes with defined SCS exposure (doses) over 
time using the different exposure measures. We used an 
incident (new) user study design that allowed us to capture 
adverse outcomes of interest from the first SCS prescription.24 
We followed patients from the time of SCS initiation until the 
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time they experienced an event or were otherwise censored. 
The use of large UK databases containing longitudinal medi-
cal record data allowed us to examine a median of almost 
10 years before the first SCS prescription to exclude prior 
SCS use, with subsequent follow-up of a median of 7 years, 
much longer than prior studies in asthma with reported mean 
and median follow-up periods of 1–5 years.7–9,15,25 Moreover, 
earlier studies examined effects of ongoing (rather than ini-
tiating) SCS exposure7,8,25–27 or ruled out previous exposure 
for only ≤12 months before the index prescription.9,15
Most prior studies included limited patient populations, 
ie, those classified as having severe asthma7–9,25 or those 
prescribed SCS for prespecified lengths of time.26,27 Studies 
from the USA included low-income7,8 or employed15,25–28 
populations, selective populations with limited or better-than-
average access to care, respectively. Instead, the majority of 
people in the UK are registered with GPs, who administer 
primary care and serve as the gate-keeper for secondary 
care; thus, the CPRD and OPCRD include data from a broad, 
representative patient population, supporting the generaliz-
ability of our findings.
Our study has a number of other strengths. The OPCRD 
and CPRD are well-established databases whose large size, 
high data quality, and granularity enabled us to study the 
association between corticosteroid exposure and the risk of 
multiple different adverse outcomes. The data pertaining to 
drug use and disease diagnoses are recorded prospectively 
and therefore were not influenced by recall bias.
Study limitations include those applicable to all histori-
cal database studies, including the potential for errors in 
documentation, as the data collected were not intended for 
research purposes. This does, however, have the benefit of 
potentially eliminating researcher bias in the collection of 
the data. We matched patients on a small number of char-
acteristics (sex, index date, and available HES linkage) and 
then adjusted for multiple confounders in the analyses. For 
the construction of the initial study cohort, more than 24 mil-
lion non-SCS patients’ records were available for matching. 
Adding age with a maximum caliper to the matching criteria 
would have resulted in a sizeable increase in  computing 
time. Therefore, for practical reasons, it was decided to 
handle confounding by age at the analysis level. Age was 
always included as a confounder, and inhaled corticosteroid 
exposure was considered as a potential confounder, in each 
model. The patients in the SCS arm were on average 5 years 
older than those in the non-SCS arm, and a greater percent-
age of patients were obese and current smokers. The two 
arms differed in several other characteristics, suggesting a 
greater asthma-related disease burden for patients prescribed 
SCS, as would be expected. However, we do not consider 
asthma severity to be associated with the onset of adverse 
outcomes, with the possible exception of pneumonia; 
thus, we suspect these findings could not have introduced 
much bias. We handled residual confounding during model 
building, drawing on a large list of potential confounders 
assembled from extensive experience with observational 
research in respiratory disease. Nonetheless, there remains 
the possibility of residual confounding from unrecognized 
and/or unmeasured factors.
Information on SCS exposure was drawn from prescribing 
records, which could lead to some misclassification because 
we could not establish whether the prescriptions were dis-
pensed (although prescribing records from the CPRD are 
considered reliable29) nor whether patients adhered to the 
SCS prescribed regimen. There is also the likelihood of bias 
in the detection of certain outcomes such as diabetes mellitus 
and osteoporosis in the SCS arm, as patients may be more 
likely to be screened for these conditions while receiving 
corticosteroid therapy.13 For about one-quarter of patients, 
there were fewer than 4 years of available history, which 
could have resulted in unaccounted prior SCS exposure and 
an underestimation of the true effects. Further potential for 
underestimation could have resulted from our inclusion of 
only the first outcome event, censoring patients after the 
onset of any outcome, thereby excluding recurrent events. 
Finally, the influence of obesity on outcomes could not be 
evaluated, as this was not a main study objective. Therefore, 
obesity was included as a covariate (Table S2) and not as an 
exposure in statistical models.
Conclusions
Our findings in a broad asthma population initiating SCS, 
including both acute and maintenance SCS, and followed 
over a median exposure period of over 7 years indicate that 
increasing cumulative exposure and increasing mean daily 
exposure to SCS places patients at a high risk of poten-
tially life-changing SCS-related adverse outcomes. The 
onset of some outcomes was associated with cumulative 
SCS  exposure of only 0.5–<1 g, equivalent to four lifetime 
courses of SCS. These findings underscore the importance 
of improving the awareness of SCS-related adverse effects 
in patients with asthma and support the need for continuing 
development and identification of alternative treatments for 
treating asthma exacerbations and for patients with severe 
asthma to reduce exposure to SCS. In conclusion, our find-
ings suggest urgent need for reappraisal of when patients 
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need specialist care and consideration of effective steroid-
sparing medications.
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